What is it about?

The first automatic chemiluminescent immunoassay for a novel biomarker NT-IGFBP-4 was developed using fragment-specific monoclonal antibodies, demonstrating excellent analytical performance and clinical potential in heart failure.

Featured Image

Read the Original

This page is a summary of: An automatic chemiluminescence immunoassay for a novel biomarker NT-IGFBP-4: analytical performance and clinical relevance in heart failure, Clinical Chemistry and Laboratory Medicine (CCLM), August 2025, De Gruyter,
DOI: 10.1515/cclm-2025-0378.
You can read the full text:

Read

Contributors

Be the first to contribute to this page